Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Anal cancer is a disease in which malignant cancerous cells form in the anal tissue. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we are confident that we can provide the best vaccine development services for anal cancer.
Most anal cancers are associated with human papillomavirus (HPV) infection. Symptoms of anal cancer include bleeding from the anus or rectum or a mass near the anus. Nearly 9 out of 10 anal cancers are squamous cell carcinomas. These tumors begin with squamous cells in most of the anal canal and anal margin. Persistent HPV infection is highly associated with the development of anal cancer. Chronic infection with HPV can lead to tumor progression from infected tissue to aggressive cancer.
Like other HPV-related cancers, anal cancer therapy progresses gradually over years. The combination of antibody immunotherapy and cancer vaccine is the best therapy in recent research. Vaccination reduces the lifetime risk of anal cancer and may be a cost-effective intervention.
Antigens highly expressed in most cancers, known as cancer-associated antigens, and abnormal proliferation of some cells are key points of concern for vaccine development. Here are some targets of anal cancer.
For advanced anal cancer, although anti-PD1/L1 immunotherapy is effective, the vast majority of chemically refractory conditions do not benefit from this monotherapy. Therapeutic anal cancer vaccines can enhance or synergize the efficacy of other immunotherapies.
By activating anti-tumor responses, such as the expansion and activation of tumor-specific T cells, anti-cancer vaccines can restore the body's immunity. Tumor-targeting vaccines can prevent tumor cells from escaping immune surveillance and activate the immune system to destroy cancer cells, which is an important breakthrough in the therapy of anal cancer. Therefore, Alfa Cytology is working on therapeutic anal cancer vaccine development services. In addition, we also provide neoantigen recognition and identification services.
Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.